Taitacept
Phase 2Protein / enzyme
Taitacept is one of 11 small molecule programs targeting Encephalitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Encephalitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Decadron
AAspen Global Incorporated
Approved
Acanya
PfizerPreclinical
Opdivo
Bristol-Myers SquibbPreclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Wellcovorin
EEastern Cooperative Oncology Group
Preclinical
ART5803
AArialys Therapeutics
Phase 2
Zovirax
BBp Consulting, Inc
Preclinical
Taitacept
BBeijing Tongren Hospital
Phase 2
Calculus Bovis Sativus
TTongji Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Encephalitis1 trial
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Recruiting·—·Phase 2·NCT06510283·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Taitacept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Tongren Hospital